Introduction
T hhis is an interesting case report and discussion, especially with the trial of aerosolized reduced glutathione in a patient with the diagnosis of chronic interstitial lung disease (ILD) with variable fibrosis in the pulmonary interstitium. Interstitial pulmonary fibrosis (IPF) is usually characterized histologically by a spectrum of fibrosis in the alveolar walls. Clinically, the term IPF is used in cases of chronic ILD with fibrosis that fails to respond to corticosteroid treatment. Others limit the use of the term to chronic ILD with predominant fibrosis that is progressive and unresponsive to corticosteroid and other immunosuppressive agents. It is the lack of resolution of the inflammatory response in the pulmonary interstitium with the progression of fibrosis that distorts the alveolar walls and leads to restrictive lung disease and interference with gas exchange. These are the critical factors in determining prognosis of chronic ILD.
The management of this patient points out some of the problems in classification as well as the management of chronic interstitial lung disease in children. It is difficult to evaluate the effect of host factors, such as age, in the natural history of chronic ILD in children and thus in the assessment of response to various therapeutic interventions. The evaluation of the course of chronic ILD in infants and very young children is especially difficult because remodeling of the lung is occurring as a part of their normal growth as well as a response to injury. In adults, the neutrophil appears to play a very pivotal role in the amplification of the chronic inflammation in IPF, and activated macrophages release cytokines as growth factors for mesenchymal cells. It is not known how much of the information derived from clinical and research studies in adults can be extrapolated to children with chronic primary ILD.
Glucocorticosteroids have been used in the treatment of chronic ILD in both adults and Some studies report the release of high levels of oxygen-free radicals by inflammatory cells and the reduction of glutathione and other antioxidant components in the alveolar epithelial lining fluid in the lungs of patients with idiopathic pulmonary fibrosis.78
These studies were the basis of the use of the aerosolized glutathione.
Unfortunately, there has been no consensus in the definition or classification of chronic ILD in children, and thus it is difficult to evaluate the role of any proposed Hilman therapeutic agent. What is included in single case reports or review of a series of cases of this heterogeneous group of disorders of chronic ILD varies from author to author. There are no pathognomonic clinical or laboratory criteria for the diagnosis of chronic ILD in children, with the exception of the histologic examination of lung tissue. There are also some differences in the classification of the lung biopsy findings by pathologists, even if they confirm thickening of the alveolar walls due to inflammatory and immune effector cells and/or fibrosis. In addition to the more familiar terms for primary chronic ILD in children-desquamative interstitial pneumonitis (DIP), lymphoid interstitial pneumonitis (LIP), usual interstitial pneumonitis (UIP), pulmonary hemosiderosis, pulmonary alveolar proteinosis, hypersensitivity pneumonitis, pulmonary infiltrates with eosinophilia-various other terms are used, such as nonspecific interstitial pneumonitis. It has been suggested that bronchiolitis obliterans interstitial pneumonitis, one of the histologic types of ILD, differs in clinical spectrum and prognosis from other types of primary chronic ILD. Bronchiolitis obliterans can be associated with known causes such as adenovirus as well as unknown causes. Bronchiolitis obliterans organizing pneumonia is a term that often refers to a specific type of ILD due to unknown etiology. Rigante et al are to be commended on obtaining a lung biopsy for documentation of ILD. The biopsy was obtained after months of symptoms of dry cough, dyspnea with medium exertion, a chest roentgenogram showing diffuse infiltrates, and computed tomography of chest showing diffuse interstitial involvement. The lung biopsy showed interstitial fibrosis with focal lymphocytic infiltration. In this patient report, there was a clinical improvement with reduction of cough and improved exercise tolerance after treatment with corticosteroids and azathioprine, although there was no improvement in the pulmonary functions. With continued use of corticosteroids and the trial of aerosolized reduced glutathione there was improvement in pulmonary function studies. It is difficult to determine the role of glutathione in a single case report, but the report leads us to hope for better therapies for this devastating group of pulmonary diseases.
